Background: Pentraxin 3 (PTX3) is a novel vascular inflammatory marker which increases in vascular events such as diabetes mellitus. The aim of this study was to investigate the relationship between serum PTX3 levels and gestational diabetes mellitus (GDM). Methods: This prospective observational study was comprised of 88 pregnant women with singleton pregnancies. The subjects were classified into 3 groups according to their response to a 50-gram glucose challenge test (GCT) and a 100-gram oral glucose tolerance test: control group (n = 28), impaired glucose tolerance group (n = 30), and GDM group (n = 30). Serum PTX3 levels were measured to examine the relationship between GDM and GCT values. Results: Significant differences in PTX3 levels were observed among the 3 groups in the sample (F = 7.598; p = 0.001). The mean PTX3 value was found to be significantly higher in the GDM group (3.17 ± 1.16 ng/ml) than in the control group (2.20 ± 0.83 ng/ml; p = 0.001). A significant positive correlation between PTX3 and GCT values was detected (r = 0.289; p = 0.008). Conclusion: Maternal serum PTX3 levels were found to be significantly related to high blood glucose levels. This may be an indicator of vascular pathology in GDM around the time of an oral glucose tolerance test.

Keywords:
Pentraxin 3, Gestational diabetes mellitus, Vascular inflammation, Pregnancy, Inflammation
1.
Metzger BE, Coustan DR: Summary and recommendations of the Fourth International Workshop-Conference on Gestational Diabetes Mellitus. Diabetes Care 1998;21(suppl 2):B161-B167.
2.
Li C, Qiao B, Zhan Y, Peng W, Chen ZJ, Sun L, Zhang J, Zhao L, Gao Q: Association between genetic variations in MTNR1A and MTNR1B genes and gestational diabetes mellitus in Han Chinese women. Gynecol Obstet Invest 2013;76:221-227.
3.
Wiznitzer A, Mayer A, Novack V, et al: Association of lipid levels during gestation with preeclampsia and gestational diabetes mellitus: a population-based study. Am J Obstet Gynecol 2009;201:482.e1-8.
4.
De Caterina R: Endothelial dysfunctions: common denominators in vascular disease. Curr Opin Lipidol 2000;11:9-23.
5.
Yilmaz MI, Axelsson J, Sonmez A, et al: Effect of renin angiotensin system blockade on pentraxin 3 levels in type-2 diabetic patients with proteinuria. Clin J Am Soc Nephrol 2009;4:535-541.
6.
Schalkwijk CG, Poland DCW, van Dijk W, et al: Plasma concentration of C-reactive protein is increased in type I diabetic patients without clinical macroangiopathy and correlates with markers of endothelial dysfunction: evidence for chronic inflammation. Diabetologia 1999;42:351-357.
7.
Rizzoni D, Porteri E, Guelfi D, Muiesan ML, Valentini U, Cimino A, et al: Structural alterations in subcutaneous small arteries of normotensive and hypertensive patients with non-insulin-dependent diabetes mellitus. Circulation 2001;103:1238-1244.
8.
Julia C, Czernichow S, Charnaux N, et al: Relationships between adipokines, biomarkers of endothelial function and inflammation and risk of type 2 diabetes. Diabetes Res Clin Pract 2014;105:231-238.
9.
Endemann DH, Pu Q, De Ciuceis C, et al: Persistent remodeling of resistance arteries in type 2 diabetic patients on antihypertensive treatment. Hypertension 2004;43:399-404.
10.
Rovere-Querini P, Antonacci S, Dell'Antonio G, et al: Plasma and tissue expression of the long pentraxin 3 during normal pregnancy and preeclampsia. Obstet Gynecol 2006;108:148-155.
11.
Hamad RR, Eriksson MJ, Berg E, Larsson A, Bremme K: Impaired endothelial function and elevated levels of pentraxin 3 in early-onset preeclampsia. Acta Obstet Gynecol Scand 2012;91:50-56.
12.
Cozzi V, Garlanda C, Nebuloni M, et al: PTX3 as a potential endothelial dysfunction biomarker for severity of preeclampsia and IUGR. Placenta 2012;33:1039-1044.
13.
Sari U, Kaygusuz I, Kafali H: Is pentraxin 3 a new cardiovascular risk marker in polycystic ovary syndrome? Gynecol Obstet Invest 2014;78:173-178.
14.
Garlanda C, Hirsch E, Bozza S, et al: Non-redundant role of the long pentraxin PTX3 in anti-fungal innate immune response. Nature 2002;420:182-186.
15.
Breviario F, d'Aniello EM, Golay J, et al: Interleukin-1-inducible genes in endothelial cells: cloning of a new gene related to C-reactive protein and serum amyloid P component. J Biol Chem 1992;267:22190-22197.
16.
Mantovani A, Garlanda C, Bottazzi B: PTX3/TSG14; in Oppenheim J, Feldmann M (eds): Cytokine Reference. New York, Academic Press, 2002.
17.
Alberti L, Gilardini L, Zulian A, et al: Expression of long pentraxin PTX3 in human adipose tissue and its relation with cardiovascular risk factors. Atherosclerosis 2009;202:455-460.
18.
Napoleone E, Di Santo A, Bastone A, et al: Long pentraxin PTX3 upregulates tissue factor expression in human endothelial cells: a novel link between vascular inflammation and clotting activation. Arterioscler Thromb Vasc Biol 2002;22:782-787.
19.
Rusnati M, Camozzi M, Moroni E, et al: Selective recognition of fibroblast growth factor-2 by the long pentraxin PTX3 inhibits angiogenesis. Blood 2004;104:92-99.
20.
Introna M, Vidal Alles V, Castellano M, et al: Cloning of mouse PTX3, a new member of the pentraxin gene family expressed at extrahepatic sites. Blood 1996;87:1862-1872.
21.
Rolph MS, Zimmer S, Bottazzi B, Garlanda C, Mantovani A, Hansson GK: Production of the long pentraxin PTX3 in advanced atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2002;22:10-14.
22.
Fazzini F, Peri G, Doni A, et al: PTX3 in small-vessel vasculitides: an independent indicator of disease activity produced at sites of inflammation. Arthritis Rheum 2001;44:2841-2850.
23.
National Diabetes Data Group: Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979;28:1039-1057.
24.
Matyjaszek-Matuszek B, Lenart-Lipińska M, Kowalczyk-Bołtuć J, Szlichtyng W, Paszkowski T: Correlation between atherogenic risk and adiponectin in gestational diabetes mellitus. Ann Agric Environ Med 2014;21:143-147.
25.
Ozuguz U, Isik S, Berker D, et al: Gestational diabetes and subclinical inflammation: evaluation of first year postpartum outcomes. Diabetes Res Clin Pract 2011;94:426-433.
26.
Pickup JC, Mattock, MB, Chusney, GD, Burt D: NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 1997;40:1286-1292.
27.
Myrup B, de Maat M, Rossing P, Gram J, Kluft C, Jespersen J: Elevated fibrinogen and the relation to acute phase response in diabetic nephropathy. Throm Res 1996;81:485-490.
28.
Latini R, Maggioni AP, Peri G, et al; Lipid Assessment Trial Italian Network (LATIN) Investigators: Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation 2004;110:2349-2354.
29.
Ferratini M, Ripamonti V, Masson S, et al: Pentraxin-3 predicts functional recovery and 1-year major adverse cardiovascular events after rehabilitation of cardiac surgery patients. J Cardiopulm Rehabil Prev 2012;32:17-24.
30.
Rolph MS, Zimmer S, Bottazzi B, Garlanda C, Mantovani A, Hansson GK: Production of the long pentraxin PTX3 in advanced atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2002;22:10-14.
31.
Aydogdu A, Tasci I, Tapan S, et al: High plasma level of long pentraxin 3 is associated with insulin resistance in women with polycystic ovary syndrome. Gynecol Endocrinol 2012;28:722-725.
32.
Todoric J, Handisurya A, Knapp B, Tura A, Pacini G, Kautzky-Willer A: Relationship of pentraxin 3 with insulin sensitivity in gestational diabetes. Eur J Clin Invest 2013;43:341-349.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.